Zumax Medical listed on the Innovation Tier of the National Equities Exchange and Quotations (NEEQ).

Source: Sumai Medical's indicative announcement regarding stock listing

DentalGoodNews｜On October 13, 2026, Suzhou Zumax Medical Technology Co., Ltd. (hereinafter referred to as "Zumax Medical") was officially listed for public transfer on the Innovation Tier of the National Equities Exchange and Quotations (hereinafter referred to as "NEEQ"), with the securities code "875259" and the trading method of call auction.

According to Zumax Medical's public transfer prospectus, the company's operating revenue in 2025 was RMB 354 million, an increase of 9.34% compared with RMB 323 million in 2024; net profit attributable to owners of the parent company was RMB 56.133 million, a decrease of 7.16% compared with RMB 60.46 million in 2024.

Source: Sumai Medical's public transfer prospectus

By product, dental surgical microscopes remained the main source of revenue for Zumax Medical. In 2025, revenue from this product was RMB 267 million, accounting for 75.53% of main business revenue, an increase of 7.77% compared with RMB 248 million in 2024; the proportion decreased by 1.12 percentage points from 76.65% in 2024.

Source: Sumai Medical's public transfer prospectus

By region, in 2025, overseas sales revenue was RMB 186 million, an increase of 3.25% compared with RMB 181 million in 2024; overseas sales revenue accounted for 52.75% of operating revenue, down 3.11 percentage points from 2024; domestic sales revenue was RMB 167 million, an increase of 17.05% compared with RMB 143 million in 2024, and its proportion of operating revenue rose from 44.14% to 47.25%. In overseas markets, revenue from Europe was RMB 96.052 million, down 3.93% from 2024, with its proportion decreasing from 30.92% to 27.17%; in the domestic market, the Southwest region grew the fastest, increasing from RMB 13.5426 million to RMB 22.896 million, up 69.07%.

Source: Sumai Medical's public transfer prospectus

According to previous reports by DGN, Zumax Medical completed a Pre-IPO financing round of nearly RMB 100 million in 2022, jointly invested by Jiale Capital, Suzhou High-tech Venture Capital, and Yueyin Medical Fund, with the funds mainly used for new product development and market expansion. In addition, Zumax Medical submitted an application for listing on the ChiNext Board to the Shenzhen Stock Exchange in July 2023, planning to raise RMB 508 million for expanding production of surgical microscopes and upgrading its R&D center. However, due to factors such as changes in the IPO market environment, its ChiNext listing application was terminated in April 2024.